Primary Sclerosing Cholangitis (PSC)
22
4
5
12
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 22 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
42%
5 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 12 completed trials
Clinical Trials (22)
The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis
Biodegradable Stents in Primary Sclerosing Cholangitis
Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation
Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis
A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
A POC and Dose-Ranging Study of HTD1801 in PSC Patients
Swiss Primary Sclerosing Cholangitis Cohort Study
Genomics of Primary Sclerosing Cholangitis (PSC)
Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing Cholangitis
S-adenosylmethionine (SAMe) in Patients With Primary Sclerosing Cholangitis (PSC)
Spanish Registry of Autoimmune and Cholestatic Liver Diseases (ColHai)
Endoscopy and Primary Sclerosing Cholangitis
Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
Cholangioscopy in Primary Sclerosing Cholangitis (PSC)
Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159
Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)
Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function
Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)
Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis